Citations (54)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (17)
James H Pickar, David F Archer, Risa Kagan, JoAnn V Pinkerton & Hugh S Taylor. (2017) Safety and benefit considerations for menopausal hormone therapy. Expert Opinion on Drug Safety 16:8, pages 941-954.
Read now
Read now
Santiago Palacios & Andrea Mejía. (2016) Progestogen safety and tolerance in hormonal replacement therapy. Expert Opinion on Drug Safety 15:11, pages 1515-1525.
Read now
Read now
Xu Zhao, Xiao-Fang Zhang, Yang Zhao, Xin Lin, Ning-Yin Li, Ganesh Paudel, Qiong-Ying Wang, Xiao-Wei Zhang, Xiu-Li Li & Jing Yu. (2016) Effect of combined drospirenone with estradiol for hypertensive postmenopausal women: a systemic review and meta-analysis. Gynecological Endocrinology 32:9, pages 685-689.
Read now
Read now
C. Gerlinger, K. Gude, T. Schmelter, M. Schaefers & J. Endrikat. (2015) 0.5 vs. 1.0 mg estradiol in combination with drospirenone for the treatment of hot flushes. Climacteric 18:4, pages 512-517.
Read now
Read now
A. R. Genazzani, T. Schmelter, M. Schaefers, C. Gerlinger & K. Gude. (2013) One-year randomized study of the endometrial safety and bleeding pattern of 0.25 mg drospirenone/0.5 mg 17β-estradiol in postmenopausal women. Climacteric 16:4, pages 490-498.
Read now
Read now
S. M. R. R. Lima, B. F. Reis, S. S. Yamada, S. Postigo, R. M. Grande, S. R. Botogoski, A. B. Campaner, C. K. Hueb & M. A. Longo Galvão. (2011) Effects of drospirenone/estradiol on steroid receptors and Bcl-2 in the postmenopausal endometrium. Climacteric 14:5, pages 551-557.
Read now
Read now
S-Q. Lin, L-Z. Sun, J-F. Lin, X. Yang, L-J. Zhang, J. Qiao, Z-H. Wang, Y-X. Xu, Z-A. Xiong, Y-Z. Zhou, M-L. Wang, J. Zhu, S-R. Chen, H. Su, C-S. Yang, S-H. Wang, Y-Z. Zhang & X-J. Dong. (2011) Estradiol 1 mg and drospirenone 2 mg as hormone replacement therapy in postmenopausal Chinese women. Climacteric 14:4, pages 472-481.
Read now
Read now
M. Gambacciani, G. Rosano, B. Cappagli, A. Pepe, C. Vitale & A. R. Genazzani. (2011) Clinical and metabolic effects of drospirenone–estradiol in menopausal women: a prospective study. Climacteric 14:1, pages 18-24.
Read now
Read now
Sebastián Carranza-Lira. (2009) Safety, efficacy and patient acceptability of drospirenone and estradiol in the treatment of menopausal vasomotor symptoms: a review. Clinical Interventions in Aging 4, pages 59-62.
Read now
Read now
Andrea J Rapkin & Sharon A Winer. (2007) Drospirenone: a novel progestin. Expert Opinion on Pharmacotherapy 8:7, pages 989-999.
Read now
Read now
P. Collins, G. Rosano, C. Casey, C. Daly, M. Gambacciani, P. Hadji, R. Kaaja, T. Mikkola, S. Palacios, R. Preston, T. Simon, J. Stevenson & M. Stramba-Badiale. (2007) Management of cardiovascular risk in the perimenopausal women: a consensus statement of European cardiologists and gynecologists. Climacteric 10:6, pages 508-526.
Read now
Read now
D. F. Archer. (2007) Drospirenone and estradiol: a new option for the postmenopausal woman. Climacteric 10:sup1, pages 3-10.
Read now
Read now
Jean-Michel Foidart & Thomas Faustmann. (2007) Advances in hormone replacement therapy: Weight benefits of drospirenone, a 17α-spirolactone-derived progestogen. Gynecological Endocrinology 23:12, pages 692-699.
Read now
Read now
David W. Sturdee & Alastair H. MacLennan. (2006) Not all placebos are equally pleasing. Climacteric 9:6, pages 401-403.
Read now
Read now
Ann Honebrink. (2005) Treatment of menopausal symptoms post-Women’s Health Initiative: refinement of existing treatments and development of new therapies. Expert Opinion on Emerging Drugs 10:3, pages 619-641.
Read now
Read now
R. Sitruk-Ware. (2005) Pharmacology of different progestogens: the special case of drospirenone. Climacteric 8:sup3, pages 4-12.
Read now
Read now
W. H. K. Oelkers. (2005) Drospirenone in combination with estrogens: for contraception and hormone replacement therapy. Climacteric 8:sup3, pages 19-27.
Read now
Read now
Articles from other publishers (37)
Abigail C WrightFrancesca L BeaudoinR. Brett McQueenKai YeungAshton MoradiSerina Herron-SmithEric GutierrezGrace A LinSteven D Pearson. (2023) The effectiveness and value of fezolinetant for moderate-to-severe vasomotor symptoms associated with menopause: A summary from the Institute for Clinical and Economic Review’s Midwest Public Advisory Council. Journal of Managed Care & Specialty Pharmacy 29:6, pages 692-698.
Crossref
Crossref
Amy J. Voedisch & Danit Ariel. (2020) Perimenopausal contraception. Current Opinion in Obstetrics & Gynecology 32:6, pages 399-407.
Crossref
Crossref
S Iliodromiti, W Wang, MA Lumsden, MS Hunter, R Bell, G Mishra & M Hickey. (2019) Variation in menopausal vasomotor symptoms outcomes in clinical trials: a systematic review. BJOG: An International Journal of Obstetrics & Gynaecology 127:3, pages 320-333.
Crossref
Crossref
Soyi Lim, Yun Hwan Kim, Kwang-Beom Lee & Jong-Min Lee. (2018) The influence of hormone therapy with drospirenone-estradiol on endometrioid type endometrial cancer patients. Journal of Gynecologic Oncology 29:5.
Crossref
Crossref
S. A. Gasparyan, L. D. Drosova & A. A. Khripunova. (2017) THE EFFECT OF LOW-DOSE DROSPIRENONE AND 17β-ESTRADIOL FOR CORRECTION OF THE MANIFESTATIONS OF CLIMACTERIC SYNDROME IN POSTMENOPAUSAL WOMEN. Medical Council:2, pages 82-86.
Crossref
Crossref
G Sarri, H Pedder, S Dias, Y Guo & MA Lumsden. (2017) Vasomotor symptoms resulting from natural menopause: a systematic review and network meta‐analysis of treatment effects from the National Institute for Health and Care Excellence guideline on menopause. BJOG: An International Journal of Obstetrics & Gynaecology 124:10, pages 1514-1523.
Crossref
Crossref
Bo Ra ParkHye Na ParkJi Back JungEun Sil Lee, Jeong Sig KimGyu Yeon ChoiJeong Jae LeeIm Soon Lee. (2017) Efficacy and safety of drospirenone 2 mg/17β-estradiol 1 mg hormone therapy in Korean postmenopausal women. Obstetrics & Gynecology Science 60:2, pages 213.
Crossref
Crossref
Rachel Gimenes Albuquerque, Marco Alexandre Dias da Rocha, Camila Hirotsu, Helena Hachul, Edileia Bagatin, Sergio Tufik & Monica Levy Andersen. (2015) A randomized comparative trial of a combined oral contraceptive and azelaic acid to assess their effect on sleep quality in adult female acne patients. Archives of Dermatological Research 307:10, pages 905-915.
Crossref
Crossref
Lujin Li, Yinghua Lv, Ling Xu & Qingshan Zheng. (2015) Quantitative efficacy of soy isoflavones on menopausal hot flashes. British Journal of Clinical Pharmacology 79:4, pages 593-604.
Crossref
Crossref
David F. Archer, Thomas Schmelter, Matthias Schaefers, Christoph Gerlinger & Kerstin Gude. (2014) A randomized, double-blind, placebo-controlled study of the lowest effective dose of drospirenone with 17β-estradiol for moderate to severe vasomotor symptoms in postmenopausal women. Menopause 21:3, pages 227-235.
Crossref
Crossref
Gabriele Sutter, Thomas Schmelter, Kerstin Gude, Matthias Schaefers, Christoph Gerlinger & David F. Archer. (2014) Population pharmacokinetic/pharmacodynamic evaluation of low-dose drospirenone with 17β-estradiol in postmenopausal women with moderate to severe vasomotor symptoms. Menopause 21:3, pages 236-242.
Crossref
Crossref
Cristina Campos, Karina Rabello Casali, Dh?niel Baraldi, Adriana Conzatti, Alex Sander da Rosa Ara?jo, Neelam Khaper, Susana Llesuy, Katya Rigatto & Adriane Bell?-Klein. (2014) Efficacy of a Low Dose of Estrogen on Antioxidant Defenses and Heart Rate Variability. Oxidative Medicine and Cellular Longevity 2014, pages 1-7.
Crossref
Crossref
Dana Brown, Amy Henneman & Darshana Desai. (2013) Efficacy of Drospirenone-Containing Hormone Replacement Therapy to Reduce Vasomotor Symptoms of Menopause. Pharmacy 1:2, pages 193-203.
Crossref
Crossref
Luiza Schvartzman, Jos? Ant?nio Magalh?es, Fernando Monteiro de Freitas, Carolina Pereira, Julia Azevedo, Edison Capp & Maria Celeste Os?rio Wender. (2013) Effects of hormone therapy on the endometrium in postmenopausal women: a one year randomized trial of low dose oral estradiol in association with a levonorgestrel-releasing intrauterine system or drospirenone. Revista Brasileira de Sa?de Materno Infantil 13:3, pages 259-266.
Crossref
Crossref
Allison T. Siebern, Sooyeon Suh & Sara Nowakowski. (2012) Non-Pharmacological Treatment of Insomnia. Neurotherapeutics 9:4, pages 717-727.
Crossref
Crossref
Barry S. Komm & Sebastian Mirkin. (2012) The Tissue Selective Estrogen Complex: A Promising New Menopausal Therapy. Pharmaceuticals 5:9, pages 899-924.
Crossref
Crossref
Hakan Coksuer, Mustafa Koplay, Fatih Oghan, Cengiz Coksuer, Nadi Keskin & Olcay Ozveren. (2010) Effects of estradiol?drospirenone hormone treatment on carotid artery intima-media thickness and vertigo/dizziness in postmenopausal women. Archives of Gynecology and Obstetrics 283:5, pages 1045-1051.
Crossref
Crossref
C. Brock Woodis. (2010) Hormone Therapy for the Management of Menopausal Symptoms. Journal of Pharmacy Practice 23:6, pages 540-547.
Crossref
Crossref
David F. Archer. (2010) Tissue-Selective Estrogen Complexes. Drugs & Aging 27:7, pages 533-544.
Crossref
Crossref
F. Geisthövel. (2010) Hat die Hormontherapie eine positive Wirkung auf Haut und Haare der peri- und postmenopausalen Frau?Does hormone therapy have a positive effect on skin and hair of perimenopausal and postmenopausal women?. Der Gynäkologe 43:4, pages 308-312.
Crossref
Crossref
Marco Stramba-Badiale. (2009) Postmenopausal hormone therapy and the risk of cardiovascular disease. Journal of Cardiovascular Medicine 10:4, pages 303-309.
Crossref
Crossref
&NA;. (2008) Hormone replacement therapy (HRT) with drospirenone offers the additional benefit of blood pressure reduction in postmenopausal women. Drugs & Therapy Perspectives 24:2, pages 12-14.
Crossref
Crossref
M. P. Warren. (2007) Missed symptoms of menopause. International Journal of Clinical Practice 61:12, pages 2041-2050.
Crossref
Crossref
B.S. Lee, B.M. Kang, B.K. Yoon, H. Choi, H.M. Park & J.G. Kim. (2007) Efficacy and tolerability of estradiol 1mg and drospirenone 2mg in postmenopausal korean women: A double-blind, randomized, placebo-controlled, multicenter study. Maturitas 57:4, pages 361-369.
Crossref
Crossref
Johannes C Huber. (2016) Combination of Drospirenone and Estradiol: A New Hormone Therapy in Postmenopausal Women. Women's Health 3:4, pages 409-415.
Crossref
Crossref
Peng-Hui Wang, Huann-Cheng Horng, Ming-Huei Cheng, Hsiang-Tai Chao & Kuan-Chong Chao. (2007) Standard and Low-dose Hormone Therapy for Postmenopausal Women—Focus on the Breast. Taiwanese Journal of Obstetrics and Gynecology 46:2, pages 127-134.
Crossref
Crossref
Jürgen C. Dinger, Lothar A.J. Heinemann & Dörthe Kühl-Habich. (2007) The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance study on Oral Contraceptives based on 142,475 women-years of observation. Contraception 75:5, pages 344-354.
Crossref
Crossref
P.H.M. van de Weijer, Lars-Åke Mattsson & Olavi Ylikorkala. (2007) Benefits and risks of long-term low-dose oral continuous combined hormone therapy. Maturitas 56:3, pages 231-248.
Crossref
Crossref
Madhavi Mallareddy, Vladimir Hanes & William B White. (2007) Drospirenone, a New Progestogen, for Postmenopausal Women with Hypertension. Drugs & Aging 24:6, pages 453-466.
Crossref
Crossref
Andrea Riccardo Genazzani, Nicola Pluchino, Silvia Begliuomini, Matteo Pieri, Manolo Centofanti, Letizia Freschi, Elena Casarosa & Michele Luisi. (2007) Drospirenone increases central and peripheral β-endorphin in ovariectomized female rats. Menopause 14:1, pages 63-73.
Crossref
Crossref
Santiago Palacios, Jean-Michel Foidart & Andrea R. Genazzani. (2006) Advances in hormone replacement therapy with drospirenone, a unique progestogen with aldosterone receptor antagonism. Maturitas 55:4, pages 297-307.
Crossref
Crossref
May WahabFarook Al-Azzawi. (2016) Current State of Hormone Replacement Therapy: The Case for Using Trimegestone. Women's Health 2:4, pages 539-550.
Crossref
Crossref
Lee P. Shulman. (2006) A Review of Drospirenone for Safety and Tolerability and Effects on Endometrial Safety and Lipid Parameters Contrasted with Medroxyprogesterone Acetate, Levonorgestrel, and Micronized Progesterone. Journal of Women's Health 15:5, pages 584-590.
Crossref
Crossref
Malcolm Whitehead. (2016) Hormone replacement therapy with estradiol and drospirenone: An overview of the clinical data. British Menopause Society Journal 12:1_suppl, pages 4-7.
Crossref
Crossref
T. Strowitzki. (2005) Kombinierte Hormonersatztherapie mit 1 mg Östradiol und 2 mg DrospirenonCombined hormone replacement therapy with 1 mg estradiol and 2 mg drospirenone. Gynäkologische Endokrinologie 3:1, pages 55-59.
Crossref
Crossref
. (2004) Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 14:1.
Crossref
Crossref
Lothar A J Heinemann & J??rgen Dinger. (2004) Safety of a New Oral Contraceptive Containing Drospirenone. Drug Safety 27:13, pages 1001-1018.
Crossref
Crossref